Jubilant Cadista Prochlorperazine Tablets Recall: Subpotent Drug Risk
Jubilant Cadista recalls 5mg Prochlorperazine tablets due to subpotent drug levels. Affected lots may not contain enough active ingredient for effective treatment.
Lower-risk recall
Subpotent Drug: Out of specification for assay at the 18-month stability timepoint.
Contact the company
What happened, in plain English
Jubilant Cadista is recalling 5mg Prochlorperazine Maleate tablets that may have insufficient active ingredient. This could mean the medication isn't effective for treating conditions like nausea or vomiting. Read more at govinfonow.com/recall/34075-jubilant-cadista-prochlorperazine-tablets-recall-subpotent-drug-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/34075-jubilant-cadista-prochlorperazine-tablets-recall-subpotent-drug-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0096-2023
Cite this page
“Jubilant Cadista Prochlorperazine Tablets Recall: Subpotent Drug Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34075-jubilant-cadista-prochlorperazine-tablets-recall-subpotent-drug-risk. Based on FDA recall #D-0096-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0096-2023%22&limit=1).
Why it’s dangerous
The tablets failed quality testing at the 18-month stability point, meaning they may contain less active ingredient than labeled. This could lead to ineffective treatment if the medication isn't working as intended.
Who’s affected
Prescription patients who received these specific tablets from Jubilant Cadista. Those with medical conditions requiring precise medication dosing may be most affected.
How to tell if you have this one
Check for the product name 'Prochlorperazine Maleate Tablets, USP 5mg, 100 tablets, RX Only'. Look for the lot number 21P0336 and expiration date 04/2023 on the packaging.
- Brand
Jubilant Cadista- Category
Drug
What to do — step by step
Check Medication Details
Verify the lot number and expiration date on the packaging to confirm if your tablets are affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
Is this a safety risk?
This is a low-risk recall as the tablets may not be effective, not a risk of serious injury or harm.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0096-2023 (December 27, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0096-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.